{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:35:02Z","timestamp":1780328102345,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ceftriaxone resistance in the Enterobacterales is typically the result of production of ESBLs or AmpC \u03b2-lactamases. The genes encoding these enzymes are often co-located with other antibiotic resistance genes leading to resistance to aminoglycosides, quinolones and trimethoprim\/sulfamethoxazole. Carbapenems are stable to ESBLs and AmpC giving them reliable in vitro activity against producers of these \u03b2-lactamases. In contrast, piperacillin\/tazobactam and amoxicillin\/clavulanate are compromised by co-production of OXA-1, which is not inhibited by tazobactam or clavulanate. These in vitro findings provide an explanation for the MERINO trial outcomes, where 3.7% (7\/191) randomized to meropenem died compared with 12.3% (23\/187) randomized to piperacillin\/tazobactam as definitive treatment of bloodstream infection due to ceftriaxone-resistant organisms. No randomized trials have yet put cefepime and carbapenems head to head, but some observational studies have shown worse outcomes with cefepime. We argue that carbapenems are the antibiotics of choice for ceftriaxone-resistant Enterobacterales.<\/jats:p>","DOI":"10.1093\/jacamr\/dlab013","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T15:07:55Z","timestamp":1612451275000},"source":"Crossref","is-referenced-by-count":15,"title":["PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales"],"prefix":"10.1093","volume":"3","author":[{"given":"David L","family":"Paterson","sequence":"first","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), RBWH Campus, Brisbane, Australia"},{"name":"Infectious Diseases Unit, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-2434","authenticated-orcid":false,"given":"Burcu","family":"Isler","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), RBWH Campus, Brisbane, Australia"},{"name":"Infectious Diseases Unit, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-0345","authenticated-orcid":false,"given":"Patrick N A","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), RBWH Campus, Brisbane, Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Brisbane, Australia"},{"name":"Central Microbiology Laboratory, Pathology Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"2021052708204963000_dlab013-B1","author":"WHO","year":"2017"},{"key":"2021052708204963000_dlab013-B2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2021052708204963000_dlab013-B3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.2018.19345","article-title":"Antibiotics for ceftriaxone-resistant Gram-negative bacterial bloodstream infections","volume":"321","author":"Rodr\u00edguez-Ba\u00f1o","year":"2019","journal-title":"JAMA"},{"key":"2021052708204963000_dlab013-B4","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, \u03b2-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021052708204963000_dlab013-B5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.2018.12565","article-title":"Carbapenem-sparing therapy for extended-spectrum \u03b2-lactamase\u2013producing E coli and Klebsiella pneumoniae bloodstream infection: the search continues","volume":"320","author":"Hayden","year":"2018","journal-title":"JAMA"},{"key":"2021052708204963000_dlab013-B6","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2021052708204963000_dlab013-B7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1469-0691.2007.01856.x","article-title":"Breakpoints for intravenously used cephalosporins in Enterobacteriaceae\u2013EUCAST and CLSI breakpoints","volume":"14 Suppl 1","author":"Kahlmeter","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2021052708204963000_dlab013-B8","author":"CLSI","year":"2016"},{"key":"2021052708204963000_dlab013-B9","doi-asserted-by":"crossref","first-page":"ofw132.","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021052708204963000_dlab013-B10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2005.06.004","article-title":"Pharmacodynamics of intermittent and continuous infusion piperacillin\/tazobactam and cefepime against extended-spectrum \u03b2-lactamase-producing organisms","volume":"26","author":"Reese","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"2021052708204963000_dlab013-B11","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052708204963000_dlab013-B12"},{"key":"2021052708204963000_dlab013-B13"},{"key":"2021052708204963000_dlab013-B14","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052708204963000_dlab013-B15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021052708204963000_dlab013-B16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021052708204963000_dlab013-B17","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","author":"Wunderink","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021052708204963000_dlab013-B18","doi-asserted-by":"crossref","first-page":"e02447","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052708204963000_dlab013-B19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021052708204963000_dlab013-B20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021052708204963000_dlab013-B21","doi-asserted-by":"crossref","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"5","author":"Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/1\/dlab013\/38275217\/dlab013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/1\/dlab013\/38275217\/dlab013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T08:26:16Z","timestamp":1622103976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab013\/6146931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab013","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,1,18]]},"article-number":"dlab013"}}